The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide ...

The Hims brand has primed people to view both their everyday health and the natural-aging processes as problems that can be ...

Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

Hims & Hers' future growth is expected from personalized solutions, with potential to expand the subscriber base by millions.

Hims has a great deal of meme potential, which could benefit the company by effectively acting as free advertising. Read more ...

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

Shares of Hims & Hers rose 5.2% Monday after the telehealth provider ran an advertisement on Super Bowl Sunday highlighting the company's efforts to fight the obesity epidemic in America. But Heard on ...

Hims & Hers Health (HIMS) stock moves a notch higher Monday morning after the company's weight-loss drug ad played during the ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Hims and Hers has been slammed for its Super Bowl commercial that admonished Americans for being obese and shamed the healthcare industry - then promoted its own weight loss drugs.  The 60-second ...